Education
About Us
Working with TipRanks
Follow Us
Voyager Therapeutics Inc. (VYGR)
:VYGR
VYGR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.56 - $10.66
Previous CloseN/A
Volume91.62K
Average Volume (3M)397.17K
Market Cap
$200.95M
Enterprise Value$38.42M
Total Cash (Recent Filing)$71.37M
Total Debt (Recent Filing)$43.73M
Price to Earnings (P/E)5.0
Beta1.10
Next Earnings
May 13, 2025EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.72
Shares Outstanding55,206,886
10 Day Avg. Volume379,589
30 Day Avg. Volume397,172
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.68
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.48
Enterprise Value/Ebitda-0.49
Forecast
1Y Price Target
$15.13Price Target Upside315.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe VY7523 anti-tau antibody is advancing in clinical development with a favorable safety profile, as demonstrated by the absence of serious adverse events in trials.
Pipeline ProgressThe company has a robust pipeline and multiple upcoming catalysts, which are expected to add significant value.
Strategic PartnershipsVoyager Therapeutics remains well-capitalized, with a cash runway into mid-2027, and its strategic partnerships provide additional potential milestone payments of up to $8.2 billion.
Bears Say
Data Readouts TimelineThe timeline for the initial tau imaging data remains unchanged, which means a longer wait for data readouts.
Financial PerformanceFY24 total revenue of $80mm was below consensus expectations.
Research And Development ExpensesR&D of $127.4mm was above consensus expectations, indicating higher than expected research and development expenses.
---
Ownership Overview
2.73% Insiders
12.80% Mutual Funds
29.88% Other Institutional Investors
44.23% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VYGR FAQ
What was Voyager Therapeutics Inc.’s price range in the past 12 months?
Voyager Therapeutics Inc. lowest stock price was $3.56 and its highest was $10.66 in the past 12 months.
What is Voyager Therapeutics Inc.’s market cap?
Voyager Therapeutics Inc.’s market cap is $200.95M.
When is Voyager Therapeutics Inc.’s upcoming earnings report date?
Voyager Therapeutics Inc.’s upcoming earnings report date is May 13, 2025 which is in 47 days.
How were Voyager Therapeutics Inc.’s earnings last quarter?
Voyager Therapeutics Inc. released its earnings results on Mar 11, 2025. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.367 by -$0.223.
Is Voyager Therapeutics Inc. overvalued?
According to Wall Street analysts Voyager Therapeutics Inc.’s price is currently Undervalued.
Does Voyager Therapeutics Inc. pay dividends?
Voyager Therapeutics Inc. does not currently pay dividends.
What is Voyager Therapeutics Inc.’s EPS estimate?
Voyager Therapeutics Inc.’s EPS estimate is -0.45.
How many shares outstanding does Voyager Therapeutics Inc. have?
Voyager Therapeutics Inc. has 55,206,886 shares outstanding.
What happened to Voyager Therapeutics Inc.’s price movement after its last earnings report?
Voyager Therapeutics Inc. reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.367. Following the earnings report the stock price went up 2.267%.
Which hedge fund is a major shareholder of Voyager Therapeutics Inc.?
Currently, no hedge funds are holding shares in VYGR
---
Voyager Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.13 (315.66% Upside)
$15.13 (315.66% Upside)
Blogger Sentiment
Bullish
VYGR Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 278.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $176.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.67%
12-Months-Change
Fundamentals
Return on Equity
10.22%
Trailing 12-Months
Asset Growth
44.59%
Trailing 12-Months
Company Description
Voyager Therapeutics Inc.
Voyager Therapeutics, Inc. (VYGR) is a biotechnology company focused on developing gene therapies for severe neurological diseases. The company operates within the biopharmaceutical sector, utilizing its proprietary adeno-associated virus (AAV) vector technology platform to advance therapies targeting central nervous system disorders. Their pipeline includes treatments for conditions such as Parkinson's disease, Huntington's disease, and other neurological disorders.
---
VYGR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with significant advancements and strong financial positioning. Despite a setback in the SOD1 silencing program, the progress in tau-targeting therapies and potential substantial milestone payments from partnerships highlight a promising future.Read More>---
VYGR Stock 12 Month Forecast
Average Price Target
$15.13
▲(315.66% Upside)
Technical Analysis
Sangamo Biosciences
―
Bluebird Bio
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering VYGR
1 Year
1 Year Success Rate
9/20 ratings generated profit
1 Year Average Return
-5.22%
reiterated a buy rating 5 months ago
Copying Jack Allen's trades and holding each position for 1 Year would result in 45.00% of your transactions generating a profit, with an average return of -5.22% per trade.
---